ZIOPHARM Oncology Inc (ZIOP) Stock
ZIOP is no longer traded. ZIOPHARM Oncology was delisted from the Nasdaq in January 2022.
Prices on this page are historical; the last trade was January 27, 2022 at $0.83.
ZIOPHARM Oncology stock price history
ZIOP final trading statistics
- Final close
- $0.83
- Final trading day
- Jan 27, 2022
- Market cap at delisting
- $178.36M
- Shares outstanding
- 216.15M
- Final 52-week range
- $0.77 – $5.95
- Avg. volume (final 3 mo.)
- 2,558,495
- All-time high (split-adj.)
- $10800.00 · Aug 2005
- All-time low (split-adj.)
- $7.65 · May 2009
- Return since IPO
- -99.9%
- Beta
- 1.69
- Book value / share
- $0.32
- Price / book
- 2.58
ZIOPHARM Oncology annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2020 | $0.00 | -$80.0M | -$0.39 |
| FY2019 | $0.00 | -$117.8M | -$0.69 |
| FY2018 | $146.0K | -$53.1M | $0.89 |
| FY2017 | $6.39M | -$54.3M | -$0.54 |
| FY2016 | $6.86M | -$165.3M | -$1.32 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About ZIOPHARM Oncology Inc
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
ZIOPHARM Oncology stock FAQ
What happened to ZIOPHARM Oncology stock?
ZIOPHARM Oncology stock was delisted from the Nasdaq. Its final close was $0.83 on January 27, 2022.
Is ZIOP stock still trading?
No. ZIOP was delisted from the Nasdaq in January 2022 and no longer trades on a U.S. exchange.
What was the last price of ZIOP stock?
ZIOP closed at $0.83 on its final trading day, January 27, 2022, for a market value of about $178.36M.
What were ZIOPHARM Oncology's revenue and earnings in its last full fiscal year?
ZIOPHARM Oncology reported revenue of $0.00 and net income of -$80.0M in fiscal 2020, its last full year as a public company.
When did ZIOPHARM Oncology go public?
ZIOPHARM Oncology Inc stock began trading on August 24, 2005.